CellCentric
Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers.
Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers.
CellCentric is a UK-based biotechnology startup founded in 2003 that is making waves in the field of cancer treatment. Their slogan, "Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers," encapsulates their mission. The company's key focus is on inobrodib, the first small molecule drug targeting twin proteins p300 and CBP. This drug is currently in Phase I/II clinical trials, showing promise in treating specific solid tumors and haematological malignancies, addressing critical unmet medical needs in cancer treatment. The latest milestone for CellCentric was a $25.00M Corporate Round investment on 11 July 2023, with Pfizer among the investors. This injection of funding marks a pivotal point in the company's journey, providing the means to further advance their groundbreaking drug and potentially revolutionize cancer therapy. With their pioneering approach and a strong backing from established industry players, CellCentric is at the forefront of developing innovative solutions that could significantly impact the future of cancer treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | £27.16M | 1 |
|
24 Jul 2024 |
| Venture Round | Unknown | 2 |
|
26 Jan 2022 |
| Venture Round | $33.00M | 1 | Morningside Venture Investments | 22 Oct 2020 |
| Venture Round | $26.00M | 1 |
|
15 May 2018 |
| Venture Round | Unknown | 1 |
|
01 Jun 2017 |
No recent news or press coverage available for CellCentric.
We care about your data, and we'd love to use cookies make your experience better.
